Intensification of diabetes therapy and time until A1C goal attainment among patients with newly diagnosed type 2 diabetes who fail metformin monotherapy within a large integrated health system

Diabetes Care

Volumn 39, Issue 9, 2016, Pages 1527-1534

  Pantalone, Kevin M ^a   Wells, Brian J ^b   Chagin, Kevin M ^a   Ejzykowicz, Flavia ^c   Yu, Changhong ^a   Milinovich, Alex ^a   Bauman, Janine M ^a   Kattan, Michael W ^a   Rajpathak, Swapnil ^c   Zimmerman, Robert S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIETARY INTAKE; DRUG TREATMENT FAILURE; ELECTRONIC HEALTH RECORD; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; SURVIVAL ANALYSIS; TREATMENT DURATION; AGED; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EVALUATION STUDY; HYPERGLYCEMIA; MIDDLE AGED; MOTIVATION; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TIME TO TREATMENT; TREATMENT FAILURE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; GOALS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT FAILURE;

EID: 84986190012     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0227     Document Type: Article

References (16)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149
2. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21: 438-447
3. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988 2010. Diabetes Care 2013;36:2271-2279
4. Fu AZ, Qiu Y, Davies MJ, Radican L, Engel SS. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab 2011;13:765-769
5. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995;44:1249-1258
6. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281:2005-2012
7. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia 2003;46(Suppl. 1):M44-M50
8. Blonde L. Current challenges in diabetes management. Clin Cornerstone 2005;7(Suppl. 3):S6-S17
9. Kahn SE, Haffner SM, HeiseMA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
10. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002;288:2868-2879
11. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004;27:384-391
12. Mata-Cases M, Benito-Badorrey B, Roura- Olmeda P, et al.; GEDAPS (Primary Care Group for the study of Diabetes) of the Catalonian Society of Family and Community Medicine. Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care. Curr Med Res Opin 2013;29:1495-1502
13. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-834
14. Rajpathak SN, Rajgopalan S, Engel SS. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. J Diabetes Complications 2014;28:831-835
15. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:100
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589